Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
495.89
+2.54 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
46
47
Next >
How Is The Market Feeling About Vertex Pharmaceuticals?
November 14, 2023
Via
Benzinga
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
November 14, 2023
You might not get a better chance to invest in these disruptive companies.
Via
The Motley Fool
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher
November 14, 2023
These stocks look reasonably priced today considering their long-term prospects.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
November 12, 2023
Most stocks aren't truly revolutionary. These really are.
Via
The Motley Fool
1 No-Brainer Stock to Buy and Hold for 10 Years
November 11, 2023
This company has been in the news for much of the year.
Via
The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
November 11, 2023
Investors shouldn't have to deliberate for too long about these great stocks.
Via
The Motley Fool
What 10 Analyst Ratings Have To Say About Vertex Pharmaceuticals
November 07, 2023
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Exploring NASDAQ:VRTX's quality characteristics.
October 30, 2023
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.
Via
Chartmill
4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
November 11, 2023
A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
November 10, 2023
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
November 09, 2023
Vertex shares look cheap today considering all the company has to offer.
Via
The Motley Fool
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
November 08, 2023
No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex.
Via
The Motley Fool
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus
November 07, 2023
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments.
Via
Investor's Business Daily
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results
November 07, 2023
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates.
Via
Benzinga
Topics
Earnings
Exposures
Financial
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
November 07, 2023
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
November 07, 2023
VRTX earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
November 06, 2023
Roku vaulted 50% to become Ark Innovation's top holding.
Via
Investor's Business Daily
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields
November 06, 2023
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
November 03, 2023
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...
Via
Benzinga
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
November 03, 2023
The meeting went almost as well as could be expected.
Via
The Motley Fool
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
November 02, 2023
This stock could be a long-term winner, thanks to its game-changing technology.
Via
The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
November 01, 2023
Via
Benzinga
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
November 01, 2023
The agency could soon approve a potential cure for sickle cell disease .
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
October 28, 2023
4x returns in just a decade is quite an attainable result for these companies.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.